The current price for Spinraza is $750,000 for the first year and $375,000 for every year after for the life of the patient. The Institute for Clinical and Economic Review (ICER), a drug-pricing watchdog organization, issued a Final Evidence Report and Report-at-a-Glance assessment comparing the drug’s effectiveness and value and its price. The first year of treatment will cost $750,000, and $375,000 per year after that. According to public pricing database PriceRx, Biogen Inc (NASDAQ: BIIB)'s Spinraza could cost $125,000 per dose. It costs $2.125 million per patient. It is approved for all forms of SMA, types 0 through 5. The first two years of treatment with Spinraza cost around 50% of one Zolgensma infusion, but Spinraza treatments must continue for life at a cost of $375,000 each year. A carton of Spinraza, Biogen’s new treatment for spinal muscular atrophy (SMA). But for those patients lucky enough to get it, it appears it can save their lives with a one-time treatment.
St Thomas The Apostle Daily Mass,
Highest Temperature Recorded In Montreal,
Chester County Obituaries 2020,
Chronic Fatigue Syndrome Latest Research 2019,
Optometry Abbreviations Pdf,
Perfume Making Ingredients,
Assassin's Creed: Bloodlines Walkthrough,